Baseline model: baseline predictors of failure to apply T2T-LDA during 2-year followup of the RA BIODAM cohort.
| Variables | Univariable OR (95% CI), N = 544–571 | Univariable p | Multivariable OR (95% CI), N = 549 |
|---|---|---|---|
| Age, yrs | 1.01 (1.00–1.01) | 0.096 | ¥ |
| Sex, female | 1.01 (0.81–1.25) | 0.963 | † |
| Disease duration, yrs | 1.00 (0.99–1.02) | 0.528 | † |
| Education, yrs | 0.97 (0.95–1.00) | 0.032 | ¥ |
| No. comorbidities | 1.17 (1.08–1.26) | < 0.001 | 1.10 (1.02–1.19) |
| Current smoker | 1.24 (1.01–1.53) | 0.041 | 1.32 (1.08–1.63) |
| Type of center, academic | 0.82 (0.67–1.00) | 0.050 | 0.81 (0.66–0.99) |
| RF positivity | 0.63 (0.51–0.77) | < 0.001 | £ |
| ACPA positivity | 0.57 (0.47–0.70) | < 0.001 | £ |
| RF and/or ACPA positivity | 0.58 (0.46–0.73) | < 0.001 | 0.63 (0.50–0.80) |
| DAS44-ESR LDA | 1.06 (0.58–1.96) | 0.845 | † |
| PtGA (0–10) | 1.07 (1.03–1.12) | 0.001 | ¥ |
| PGA (0–10) | 1.07 (1.02–1.13) | 0.009 | ¥ |
| Swollen joint count (0–44) | 1.01 (1.00–1.03) | 0.075 | ¥ |
| Tender joint count (0–53) | 1.03 (1.03–1.04) | < 0.001 | 1.03 (1.02–1.04) |
| ESR, mm/h | 1.00 (1.00–1.01) | 0.516 | † |
| CRP, mg/l | 1.00 (0.99–1.00) | 0.908 | † |
| HAQ | 1.29 (1.12–1.49) | < 0.001 | ¥ |
| No. previous csDMARD | 1.02 (0.94–1.11) | 0.622 | † |
| Previous treatment with any csDMARD | 1.10 (0.91–1.33) | 0.318 | † |
↵† Not selected from the univariable analysis (p > 0.20).
↵¥ Not significant in the multivariable analysis (p > 0.05).
↵£: RF or ACPA positivity entered into multivariate model. Country added as a covariate in all univariable models and in the final multivariable model. Final model also adjusted for type of treatment (csDMARD and/or bDMARD). Values in bold face are statistically significant. T2T: treat-to-target; LDA: low disease activity; RA: rheumatoid arthritis; RF: rheumatoid factor; ACPA: anticitrullinated protein antibody; DAS44-ESR: 44-joint count Disease Activity Score based on erythrocyte sedimentation rate; PtGA: patient’s global assessment; PGA: physician’s global assessment; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biological DMARD.